OR WAIT null SECS
Patheon will showcase its biologic, small molecule API development services, and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide.
Patheon (booth 1H9) will showcase its biologic, small molecule API development services, and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide from Tuesday, Oct. 7, to Thursday, Oct. 9, in Paris Nord Villepinte, France.
The company will also introduce its new end-to-end development offering, OneSource, which now provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance and drug product development. With the launch of OneSource, Patheon will connect its services from drug substance to drug products, focusing on simplicity, speed and uncompromised quality. The company’s expertise in development services and large scale production will enable Patheon to integrate all utilized technologies in one, lean process, which will deliver additional customer value. The OneSource offering is led by Lukas Utiger, PhD, who will give a presentation at the Speaker’s Corner at CPhI/ICSE Worldwide on Wednesday, Oct. 8 at 2:00 p.m., for attendees who would like to find out more about Patheon’s full offerings.
“After much work, we are pleased to provide customers OneSource, which is available for Phase I through Phase II projects,” said Lukas Utiger, PhD, president, DPx Fine Chemicals (formerly DSM Fine Chemicals) and Integrated Offering, in a press statement. “We continue to streamline this offering and have future plans to provide similar simplicity to Phase III through commercial scale capabilities as well. We feel strongly that it is important to bring fast and simple solutions to our customers that really address their needs.”